vs

Side-by-side financial comparison of ImmunityBio, Inc. (IBRX) and McEwen Inc. (MUX). Click either name above to swap in a different company.

McEwen Inc. is the larger business by last-quarter revenue ($64.6M vs $38.3M, roughly 1.7× ImmunityBio, Inc.). McEwen Inc. runs the higher net margin — 59.0% vs -161.8%, a 220.8% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs 92.8%).

ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.

McEwen Inc (ticker MUX) is a natural resource company primarily engaged in the exploration, development, and production of gold, silver, and copper assets. Its core operations are located across North and South America, serving global commodity markets with a focus on sustainable, responsible mining practices.

IBRX vs MUX — Head-to-Head

Bigger by revenue
MUX
MUX
1.7× larger
MUX
$64.6M
$38.3M
IBRX
Growing faster (revenue YoY)
IBRX
IBRX
+314.2% gap
IBRX
407.0%
92.8%
MUX
Higher net margin
MUX
MUX
220.8% more per $
MUX
59.0%
-161.8%
IBRX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IBRX
IBRX
MUX
MUX
Revenue
$38.3M
$64.6M
Net Profit
$-61.9M
$38.1M
Gross Margin
99.0%
26.9%
Operating Margin
-169.0%
34.2%
Net Margin
-161.8%
59.0%
Revenue YoY
407.0%
92.8%
Net Profit YoY
-4.7%
563.1%
EPS (diluted)
$-0.06
$0.66

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IBRX
IBRX
MUX
MUX
Q4 25
$38.3M
$64.6M
Q3 25
$32.1M
$50.5M
Q2 25
$26.4M
$46.7M
Q1 25
$16.5M
$35.7M
Q4 24
$7.6M
$33.5M
Q3 24
$6.1M
$52.3M
Q2 24
$47.5M
Q1 24
$41.2M
Net Profit
IBRX
IBRX
MUX
MUX
Q4 25
$-61.9M
$38.1M
Q3 25
$-67.3M
$-462.0K
Q2 25
$-92.6M
$3.0M
Q1 25
$-129.6M
$-6.3M
Q4 24
$-59.2M
$-8.2M
Q3 24
$-85.7M
$-2.1M
Q2 24
$-13.0M
Q1 24
$-20.4M
Gross Margin
IBRX
IBRX
MUX
MUX
Q4 25
99.0%
26.9%
Q3 25
99.4%
15.5%
Q2 25
99.5%
26.3%
Q1 25
99.6%
28.2%
Q4 24
1.1%
Q3 24
26.4%
Q2 24
22.7%
Q1 24
14.6%
Operating Margin
IBRX
IBRX
MUX
MUX
Q4 25
-169.0%
34.2%
Q3 25
-173.5%
-16.7%
Q2 25
-269.8%
-7.2%
Q1 25
-390.1%
-21.4%
Q4 24
-919.0%
-43.4%
Q3 24
-1314.3%
-0.2%
Q2 24
-29.4%
Q1 24
-53.3%
Net Margin
IBRX
IBRX
MUX
MUX
Q4 25
-161.8%
59.0%
Q3 25
-209.8%
-0.9%
Q2 25
-350.3%
6.5%
Q1 25
-784.9%
-17.6%
Q4 24
-783.4%
-24.6%
Q3 24
-1404.0%
-4.0%
Q2 24
-27.4%
Q1 24
-49.4%
EPS (diluted)
IBRX
IBRX
MUX
MUX
Q4 25
$-0.06
$0.66
Q3 25
$-0.07
$-0.01
Q2 25
$-0.10
$0.06
Q1 25
$-0.15
$-0.12
Q4 24
$-0.08
$-0.15
Q3 24
$-0.14
$-0.04
Q2 24
$-0.26
Q1 24
$-0.41

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IBRX
IBRX
MUX
MUX
Cash + ST InvestmentsLiquidity on hand
$242.8M
$72.1M
Total DebtLower is stronger
$126.2M
Stockholders' EquityBook value
$-500.5M
$546.2M
Total Assets
$501.9M
$820.2M
Debt / EquityLower = less leverage
0.23×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IBRX
IBRX
MUX
MUX
Q4 25
$242.8M
$72.1M
Q3 25
$257.8M
$75.4M
Q2 25
$153.7M
$69.5M
Q1 25
$61.6M
$79.3M
Q4 24
$149.8M
$15.3M
Q3 24
$130.4M
$30.2M
Q2 24
$42.6M
Q1 24
$22.0M
Total Debt
IBRX
IBRX
MUX
MUX
Q4 25
$126.2M
Q3 25
$126.0M
Q2 25
$125.8M
Q1 25
$125.5M
Q4 24
$40.0M
Q3 24
$31.0M
Q2 24
$34.0M
Q1 24
$37.0M
Stockholders' Equity
IBRX
IBRX
MUX
MUX
Q4 25
$-500.5M
$546.2M
Q3 25
$-524.3M
$488.6M
Q2 25
$-570.7M
$484.5M
Q1 25
$-591.4M
$479.8M
Q4 24
$-489.1M
$495.0M
Q3 24
$-745.1M
$502.1M
Q2 24
$485.2M
Q1 24
$482.5M
Total Assets
IBRX
IBRX
MUX
MUX
Q4 25
$501.9M
$820.2M
Q3 25
$519.0M
$747.6M
Q2 25
$402.1M
$735.6M
Q1 25
$303.8M
$730.6M
Q4 24
$382.9M
$664.6M
Q3 24
$364.6M
$667.8M
Q2 24
$645.1M
Q1 24
$638.7M
Debt / Equity
IBRX
IBRX
MUX
MUX
Q4 25
0.23×
Q3 25
0.26×
Q2 25
0.26×
Q1 25
0.26×
Q4 24
0.08×
Q3 24
0.06×
Q2 24
0.07×
Q1 24
0.08×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IBRX
IBRX
MUX
MUX
Operating Cash FlowLast quarter
$-70.4M
$3.1M
Free Cash FlowOCF − Capex
$-71.3M
FCF MarginFCF / Revenue
-186.2%
Capex IntensityCapex / Revenue
2.4%
Cash ConversionOCF / Net Profit
0.08×
TTM Free Cash FlowTrailing 4 quarters
$-308.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IBRX
IBRX
MUX
MUX
Q4 25
$-70.4M
$3.1M
Q3 25
$-68.9M
$5.2M
Q2 25
$-79.7M
$478.0K
Q1 25
$-85.9M
$-1.9M
Q4 24
$-85.1M
$-1.2M
Q3 24
$-98.8M
$23.2M
Q2 24
$3.6M
Q1 24
$3.9M
Free Cash Flow
IBRX
IBRX
MUX
MUX
Q4 25
$-71.3M
Q3 25
$-69.6M
Q2 25
$-80.8M
Q1 25
$-87.0M
Q4 24
$-87.3M
Q3 24
$-101.6M
Q2 24
Q1 24
FCF Margin
IBRX
IBRX
MUX
MUX
Q4 25
-186.2%
Q3 25
-217.2%
Q2 25
-305.9%
Q1 25
-526.9%
Q4 24
-1155.4%
Q3 24
-1663.2%
Q2 24
Q1 24
Capex Intensity
IBRX
IBRX
MUX
MUX
Q4 25
2.4%
Q3 25
2.3%
Q2 25
4.1%
Q1 25
6.8%
Q4 24
28.0%
Q3 24
45.7%
Q2 24
Q1 24
Cash Conversion
IBRX
IBRX
MUX
MUX
Q4 25
0.08×
Q3 25
Q2 25
0.16×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons